Literature DB >> 2953342

Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: evidence for reversal of joint damage.

B M Weichman, T T Chau, G Rona.   

Abstract

Histopathologic evaluation of hindpaws from control rats with established adjuvant arthritis showed severe alterations in soft tissue and bone, as well as progressive, moderate-to-severe articular changes. Following treatment with etodolac for 28 days, soft tissue and articular changes were rated mild, and bone changes were rated moderate, but with remodeling. These findings indicate that etodolac partially reversed the joint damage in these rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953342     DOI: 10.1002/art.1780300419

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.

Authors:  J A Balfour; M M Buckley
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Effect of etodolac on type-II collagen-induced arthritis in mice.

Authors:  K Inoue; A Motonaga; H Suzuka; H Yoshifusa; H Fujisawa; T Nishimura; Y Inoue; F Ueda; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1993-07

3.  Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac.

Authors:  M A Hayward; G A Howard; R G Neuman; D D Wood; B M Weichman; D C Van Sickle
Journal:  Agents Actions       Date:  1989-03

4.  Effect of etodolac, a new nonsteroidal anti-inflammatory drug, in MRL/lpr mice with articular lesions.

Authors:  H Yoshida-Suzuka; Y Nakamura; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1991-07

5.  The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.

Authors:  Mennatallah A Gowayed; Amany Abdel-Bary; Rasha A El-Tahan
Journal:  BMC Pharmacol Toxicol       Date:  2021-05-01       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.